ANP Antibody (Mouse mAb) [M21G12]

Catalog No.: F4482

    Application: Reactivity:
    • Lane 1: Mouse heart, Lane 2: Rat heart
    1/
    サイズ 価格(税別) 在庫状況
    JPY 17300 国内在庫なし(納期7~10日)
    JPY 39900 国内在庫なし(納期7~10日)
    JPY 59900 お問い合わせ

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp
    よく尋ねられる質問

    キーポイント

    WB
    転写条件(ウェット): 200 mA, 60 min,Recommended to use 0.22 μm PVDF 膜の使用をお勧めします。
    推奨WB希釈率: 1:100

    使用情報

    Dilution
    1:100-1:1000
    1:100-1:200
    1:50-1:500
    Application
    WB, IP, IF, ELISA
    Source
    Mouse Monoclonal Antibody
    Reactivity
    Human, Mouse, Rat
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    17 kDa
    ポジティブコントロール Rat heart tissue; Mouse heart tissue
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.22 µm PVDF membrane is recommended )Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 60 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:100), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IF
    Experimental Protocol:
     
    Sample Preparation
    1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.
    2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.
    3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.
    4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.
     
    Fixation
    1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.
    2. Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Permeabilization
    1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.
    (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)
    Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Blocking
    Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)
    Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.
     
    Immunofluorescence Staining (Day 1)
    1. Remove the blocking solution and add the diluted primary antibody.
    2. Incubate the sample in a humidified chamber at 4°C overnight.
     
    Immunofluorescence Staining (Day 2)
    1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.
    2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.
    3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.
    4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.
    5. Wash with PBST for 3 times, 5 minutes each time.
     
    Mounting
    1. Mount the sample with an anti-fade mounting medium.
    2. Allow the slide to dry at room temperature overnight in the dark.
    3. Store the slide in a slide storage box at 4°C, protected from light.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    ANP Antibody (Mouse mAb) [M21G12] detects endogenous levels of total ANP protein.
    タンパク質の局在
    細胞突起、細胞外環境
    Uniprot ID
    P01160
    Clone
    M21G12
    Synonym(s)
    NPPA, Natriuretic peptides A, proANF, preproANP, proANP, Atriopeptigen, proANP 95-126, Auriculin-C, Atrial natriuretic factor 1-33, ANF 1-33, ANP, PND
    Background
    Atrial natriuretic peptide (ANP) is a member of the cardiac natriuretic peptide family synthesized as pre-proANP in atrial myocytes, processed in secretory granules to proANP, and then cleaved by the transmembrane serine protease corin at the time of secretion to generate the biologically active circulating hormone, which belongs to the same family as brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) and shares the conserved disulfide-bonded ring structure required for receptor binding. The mature peptide contains a central 17-residue ring formed by an intramolecular disulfide bridge flanked by flexible N- and C-terminal segments, and this ring engages guanylyl cyclase–linked natriuretic peptide receptor-A (NPR-A, also termed GC-A) on target cells to activate the intrinsic cyclase domain, increase intracellular cGMP, and initiate downstream signaling. ANP–NPR-A signaling activates cGMP-dependent protein kinase G and cGMP-regulated phosphodiesterases and ion channels, lowers cytosolic calcium in vascular smooth muscle, and produces vasodilation, while in the kidney it acts on glomerular and tubular targets to increase glomerular filtration rate, inhibit sodium reabsorption in the collecting duct, and enhance natriuresis and diuresis, thereby reducing plasma volume and arterial blood pressure. ANP also suppresses the renin–angiotensin–aldosterone system by inhibiting renin and aldosterone secretion and decreases sympathetic nervous system activity, so that the peptide functions as a coordinated counter-regulatory hormone opposing vasoconstrictor and sodium-retaining pathways and stabilizing cardiovascular and volume homeostasis. Secretion of ANP is tightly coupled to atrial wall stretch; mechanical distension of the atria by volume loading or increased venous return triggers rapid exocytosis of ANP-containing granules, and atrial tachyarrhythmias, vasoconstrictor-induced increases in preload or afterload, and endothelial factors such as endothelin and nitric oxide further modulate release, establishing atrial stretch and paracrine signaling as primary determinants of circulating ANP levels. At the transcriptional level, ANP expression is predominantly atrial under physiological conditions but becomes strongly upregulated in stressed ventricles, and the ANP gene is a well-established marker of pathological cardiac hypertrophy and remodeling, where elevated myocardial and plasma ANP reflect increased wall stress and altered hemodynamic load. In renal and cardiovascular disease, circulating ANP levels rise in states of volume expansion such as heart failure and chronic kidney disease and contribute to compensatory natriuretic and vasodilator responses, while impaired ANP signaling or reduced receptor responsiveness associate with hypertension, cardiac hypertrophy, and progression of heart failure.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください